Floatz logo

Idarubicine

Acute Promyelocytic Leukemia

Associazione Italiana Ematologia Oncologia PediatricaPhase 4 / ApprovedActive
BBB
78/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
71/ 100
Competitive Position
89/ 100

Competitive context

6 Active assets in the Acute Promyelocytic Leukemia cohort.

Asset / SponsorPhaseRating
Vesanoid
The Affiliated People's Hospital of Ningbo University
Phase 4A
Arsenic Trioxide
Quetzal Therapeutics
Phase 4BBB
Daunorubicin
Peking University People's Hospital
Phase 4BBB
Mitoxantrone
Technische Universität Dresden
Phase 4BB
Aida
PETHEMA Foundation
Phase 4BB

View all 14 →

Same molecule, other indications

Idarubicine is also rated in:

acute promyelocytic leukemiaDormant
A
Indicative ·
81 / 100
View asset →
acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22)Dormant
BBB
Indicative ·
76 / 100
View asset →
acute myeloid leukemia with 11q23 abnormalitiesDormant
BBB
Indicative ·
76 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →